Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Accumulated Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Accumulated Expenses for 6 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses changed N/A to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a N/A change, with the full-year FY2024 number at $4.6 million, up 38.24% from a year prior.
  • Accumulated Expenses was $4.0 million for Q3 2025 at Janux Therapeutics, up from $1.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.2 million in Q3 2022 to a low of $1.2 million in Q4 2021.
  • A 5-year average of $3.7 million and a median of $4.0 million in 2025 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: surged 309.44% in 2021, then tumbled 72.98% in 2023.
  • Janux Therapeutics' Accumulated Expenses stood at $1.2 million in 2021, then surged by 302.73% to $4.7 million in 2022, then decreased by 29.96% to $3.3 million in 2023, then surged by 38.24% to $4.6 million in 2024, then fell by 11.83% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Accumulated Expenses are $4.0 million (Q3 2025), $1.9 million (Q1 2025), and $4.6 million (Q4 2024).